{
  "drug_name": "Teicoplanin",
  "tradename": "Targocid",
  "usage_and_dosing": {
    "general": [
      "Teicoplanin is a parenteral glycopeptide, similar to Vancomycin, available in Europe, Asia-Pacific and Africa.",
      "In U.S. trials, doses needed to clear Staph. aureus bacteremia were toxic with the most common adverse event being the development of thrombocytopenia. Not licensed for use in the U.S.",
      "An alternative antibiotic for drug resistant genotypes.",
      "Can be administered intramuscularly (max 400 mg at any site)."
    ],
    "adult_dose": {
        "complicated_skin_and_soft_tissue_infection_pneumonia_complicated_uti": {
            "loading_dose": "6 mg/kg q12h x3 doses",
            "target_trough_fpia": ">15 µg/mL (day 3-5)",
            "maintenance_dose": "6 mg/kg q24h",
            "maintenance_target_trough_fpia": ">"
        },
        "bone_and_joint_infection": {
            "loading_dose": "12 mg/kg q12h x3-5 doses",
            "target_trough_fpia": ">20 µg/mL (day 3-5)",
            "maintenance_dose": "12 mg/kg q24h",
            "maintenance_target_trough_fpia": ">"
        },
        "endocarditis": {
            "loading_dose": "12 mg/kg q12h x3-5 doses",
            "target_trough_fpia": "30-40 µg/mL (day 3-5)",
            "maintenance_dose": "12 mg/kg q24h",
            "maintenance_target_trough_fpia": ">"
        },
        "c_difficile_infection": {
            "loading_dose": "None, see maintenance",
            "maintenance_dose": "100-200 mg orally twi days"
        },
        "fpia_note": "FPIA = Fluorescence Polarization Immunoassay"
    },
    "pediatric_dose": {
      "age_0_to_le_2_mon": "16 mg/kg IV x1 dose, then 8 mg/kg IV q24h",
      "age_2_mon_to_12_yrs": "10 mg/kg IV q12h x3 doses, then 6-10 mg/kg IV q24h",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "70-100",
    "half_life_esrd": "up to 230",
    "dose_renal_function_normal": "6-12 mg/kg IV q12h x3 doses (load), then 6-12 mg/kg IV q24h",
    "crcl_or_egfr": "CrCl >80: No dosage adjustment. CrCl 30-80: Load, then 6-12 mg/kg q48h. CrCl <30: Load, then 6-12 mg/kg q72h",
    "hemodialysis": "Not removed by HD",
    "capd": "No data",
    "crrt": "Load, then 6-12 mg/kg q48h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "ECMO: See ECMO Drug Dosing Adjustment table.",
    "Obesity: See Obesity Dosing Adjustments table."
  ],
  "adverse_effects": [
    "Hypersensitivity: fever (at 3 mg/kg 2.2%, at 24 mg/kg 8.2%), skin reactions (2.4%).",
    "Marked decrease in platelets (high dose ≥15 mg/kg/day); anemia and neutropenia can occur.",
    "Histamine-release syndrome less common than with Vancomycin."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "B3 (Australia)",
    "lactation": "Unknown if excreted into breast milk. Use only if potential benefit outweighs risk.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
        "Enterococcus faecalis, susceptible to vancomycin",
        "Staphylococcus epidermidis, methicillin-resistant (MRSE)",
        "Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others",
        "Viridans group streptococci"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "70 (6 mgkg IV q24h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "90-95",
    "volume_of_distribution_vd_l_kg_vss": "0.9-1.6 L/kg (Vss)",
    "avg_serum_half_life_hr": "70-100",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "negligible",
    "therapeutic_levels_in_csf": "No",
    "auc_ug_hr_ml": "500-600 (6 mg/kg IV, 0-inf)"
  },
  "major_drug_interactions": [
    "Use caution in patients receiving concurrent nephrotoxic or ototoxic drugs, such as aminoglycosides, amphotericin B, cyclosporine and furosemide."
  ],
  "comments": [
    "In endocarditis, Teicoplanin has often been used in combination regimens."
  ]
}
